The Ser326Cys polymorphism of hOGG1 is associated with intrahepatic cholangiocarcinoma susceptibility in a Chinese population

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 9, 2015, Pages 16294-16300

  Ding, Xiangmin ^a,b   Wang, Ke ^a   Wu, Zhengshan ^a   Yao, Aihua ^a   Li, Jiaxin ^a   Jiao, Chengyu ^a   Qian, Jianjun ^b   Bai, Dousheng ^b   Li, Xiangcheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

Author keywords

HOGG1; Intrahepatic cholangiocarcinoma; Polymorphism

Indexed keywords

GENOMIC DNA; HUMAN 8 HYDROXYGUANINE GLYCOSYLASE PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BILE DUCT CARCINOMA; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DNA ISOLATION; FEMALE; GENDER; GENE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN 8 HYDROXYGUANINE GLYCOSYLASE GENE; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84946615584     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Aljiffry M, Walsh MJ and Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gas-troenterol 2009; 15: 4240-4262.
2. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J and Investigators ABCT. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
3. Li SQ, Liang LJ, Hua YP, Peng BG, He Q, Lu MD and Chen D. Long-term outcome and prognos tic factors of intrahepatic cholangiocarcinoma. Chin Med J (Engl) 2009; 122: 2286-2291.
4. Galvan A, Ioannidis JP and Dragani TA. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet 2010; 26: 132-141.
5. Osorio A, Milne RL, Kuchenbaecker K, Vaclova T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Diez O, Ramon YCT, Konstantopoulou I, Martinez-Bouzas C, Andres Conejero R, Soucy P, McGuffog L, Barrowdale D, Lee A, Swe B, Arver B, Rantala J, Loman N, Ehrencrona H, Olopade OI, Beattie MS, Domchek SM, Nathanson K, Rebbeck TR, Arun BK, Karlan BY, Walsh C, Lester J, John EM, Whittemore AS, Daly MB, Southey M, Hopper J, Terry MB, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Hansen TV, Jonson L, Ejlertsen B, Gerdes AM, Infante M, Herraez B, Moreno LT, Weitzel JN, Herzog J, Weeman K, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Bonanni B, Mariette F, Volorio S, Viel A, Varesco L, Papi L, Ottini L, Tibiletti MG, Radice P, Yannoukakos D, Garber J, Ellis S, Frost D, Platte R, Fineberg E, Evans G, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Eccles D, Cook J, Hodgson S, Brewer C, Tischkowitz M, Douglas F, Porteous M, Side L, Walker L, Morrison P, Donaldson A, Kennedy J, Foo C, Godwin AK, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Damiola F, Poppe B, Claes K, Piedmonte M, Tucker K, Backes F, Rodriguez G, Brewster W, Wakeley K, Rutherford T, Caldes T, Nevanlinna H, Aittomaki K, Rookus MA, van Os TA, van der Kolk L, de Lange JL, Meijers-Heijboer HE, van der Hout AH, van Asperen CJ, Gomez Garcia EB, Hoogerbrugge N, Collee JM, van Deurzen CH, van der Luijt RB, Devilee P, Hebon, Olah E, Lazaro C, Teule A, Menendez M, Jakubowska A, Cybulski C, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Johannsson OT, Maugard C, Montagna M, Tognazzo S, Teixeira MR, Healey S, Investigators K, Olswold C, Guidugli L, Lindor N, Slager S, Szabo CI, Vijai J, Robson M, Kauff N, Zhang L, Rau-Murthy R, Fink-Retter A, Singer CF, Rappaport C, Geschwantler Kaulich D, Pfeiler G, Tea MK, Berger A, Phelan CM, Greene MH, Mai PL, Lejbkowicz F, Andrulis I, Mulligan AM, Glendon G, Toland AE, Bojesen A, Pedersen IS, Sunde L, Thomassen M, Kruse TA, Jensen UB, Friedman E, Laitman Y, Shimon SP, Simard J, Easton DF, Offit K, Couch FJ, Chenevix-Trench G, Antoniou AC and Benitez J. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 2014; 10: e1004256.
6. Weiss JM, Goode EL, Ladiges WC and Ulrich CM. Polymorphic variation in hOGG1 and risk of cancer: a review of the functional and epidemiologic literature. Mol Carcinog 2005; 42: 127-141.
7. Tsukino H, Hanaoka T, Otani T, Iwasaki M, Kobayashi M, Hara M, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y and Tsugane S. hOGG1 Ser326Cys polymorphism, interaction with environmental exposures, and gastric cancer risk in Japanese populations. Cancer Sci 2004; 95: 977-983.
8. Okasaka T, Matsuo K, Suzuki T, Ito H, Hosono S, Kawase T, Watanabe M, Yatabe Y, Hida T, Mitsudomi T, Tanaka H, Yokoi K and Tajima K. hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type. J Hum Genet 2009; 54: 739-745.
9. Zhang J, Dhakal IB, Greene G, Lang NP and Kadlubar FF. Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urology 2010; 75: 779-785.
10. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E and Alvaro D. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 2010; 42: 253-260.
11. Igarashi M, Watanabe M, Yoshida M, Sugaya K, Endo Y, Miyajima N, Abe M, Sugano S and Nakae D. Enhancement of lung carcinogenesis initiated with 4-(N-hydroxymethylnitrosamino)-1-(3-pyridyl)-1-butanone by Ogg1 gene deficiency in female, but not male, mice. J Toxicol Sci 2009; 34: 163-174.
12. Sampath H, Vartanian V, Rollins MR, Sakumi K, Nakabeppu Y and Lloyd RS. 8-Oxoguanine DNA glycosylase (OGG1) deficiency increases susceptibility to obesity and metabolic dysfunction. PLoS One 2012; 7: e51697.
13. Yamane A, Kohno T, Ito K, Sunaga N, Aoki K, Yoshimura K, Murakami H, Nojima Y and Yokota J. Differential ability of polymorphic OGG1 proteins to suppress mutagenesis induced by 8-hydroxyguanine in human cell in vivo. Carcinogenesis 2004; 25: 1689-1694.
14. Collins AR and Gaivao I. DNA base excision repair as a biomarker in molecular epidemiology studies. Mol Aspects Med 2007; 28: 307-322.
15. Zhang J, Zhou J, Zhang P, Wang W, Tao S and Wang M. A meta-analysis of the association between the hOGG1 Ser326Cys polymorphism and the risk of esophageal squamous cell carcinoma. PLoS One 2013; 8: e65742.
16. Ni M, Qiu J, He W and Wang X. The functional Ser326Cys polymorphism in hOGG1 is associ ated with gastric cancer risk: evidence from 1180 cases and 2444 controls. Eur J Gas-troenterol Hepatol 2012; 24: 683-687.
17. Wei B, Zhou Y, Xu Z, Xi B, Cheng H, Ruan J, Zhu M, Hu Q, Wang Q, Wang Z, Yan Z, Jin K, Zhou D, Xuan F, Huang X, Shao J and Lu P. The effect of hOGG1 Ser326Cys polymorphism on cancer risk: evidence from a meta-analysis. PLoS One 2011; 6: e27545.
18. Yuan T, Wei J, Luo J, Liu M, Deng S and Chen P. Polymorphisms of base-excision repair genes hOGG1 326cys and XRCC1 280His increase hepatocellular carcinoma risk. Dig Dis Sci 2012; 57: 2451-2457.
19. Xu Z, Yu L and Zhang X. Association between the hOGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis based on 22,475 subjects. Diagn Pathol 2013; 8: 144.
20. Ji C, Liu Z, Chen H, Guo H and Liu C. An association between hOGG1 Ser326Cys polymorphism and the risk of bladder cancer in non-smokers: a meta-analysis. BMC Cancer 2012; 12: 335.
21. Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H, Sun Q, Yan F, Yan C, Li H and Ren X. The hOGG1 Ser326Cys polymorphism contributes to digestive system cancer susceptibility: evidence from 48 case-control studies. Tumour Biol 2015; 36: 1029-38
22. Wang W, Dang S, Li Y, Sun M, Jia X, Wang R and Liu J. hOGG1 Ser326Cys polymorphism and risk of hepatocellular carcinoma among East Asians: a meta-analysis. PLoS One 2013; 8: e60178.
23. Zhang RC and Mou SH. Polymorphisms of excision repair gene XPD Lys751Gln and hOGG1 Ser326Cys might not be associated with hepatocellular carcinoma risk: a meta-analysis. Tumour Biol 2013; 34: 901-907.